EGFR and neoplasm: Among the 33 patients for whom RAS status of the primary tumor was available, 16 patients received chemotherapy plus antiangiogenic drugs while 17 received chemotherapy plus epidermal growth factor receptor (EGFR) inhibitors (see Supplementary Table 1).